Advanced search
Publication Cover
Bioscience, Biotechnology, and Biochemistry Volume 69, 2005 - Issue 9
Journal homepage
124
Views
18
CrossRef citations to date
0
Altmetric
Original Articles

Synthesis and Activity of Tyropeptin A Derivatives as Potent and Selective Inhibitors of Mammalian 20S Proteasome

Isao MOMOSENumazu Bio-Medical Research Institute, Microbial Chemistry Research Center
,
Yoji UMEZAWAMicrobial Chemistry Research Center
,
Sehei HIROSAWAHiyoshi Medicinal Chemistry Research Institute, Microbial Chemistry Research Center
,
Masatomi IIJIMANumazu Bio-Medical Research Institute, Microbial Chemistry Research Center
,
Hironobu IINUMAMicrobial Chemistry Research Center
&
Daishiro IKEDANumazu Bio-Medical Research Institute, Microbial Chemistry Research Center
Pages 1733-1742 | Received 12 Apr 2005, Accepted 01 Jun 2005, Published online: 22 May 2014

  • 1) Coux, O., Tanaka, K., and Goldberg, A. L., Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 65, 801–847 (1996).
  • 2) Voges, D., Zwickl, P., and Baumeister, W., The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu. Rev. Biochem., 68, 1015–1068 (1999).
  • 3) Maki, C. G., and Howley, P. N., Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol., 17, 355–363 (1997).
  • 4) Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M., Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science, 269, 682–685 (1995).
  • 5) Ciechanover, A., DiGiuseppe, J. A., Bercovich, B., Orian, A., Richter, J. D., Schwartz, A. L., and Brodeur, G. M., Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc. Natl. Acad. Sci. U.S.A., 88, 139–143 (1991).
  • 6) Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T., The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell, 78, 773–785 (1994).
  • 7) Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamonda, L., and Stein, R. L., Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acid. Bioorg. Med. Chem. Lett., 8, 333–338 (1998).
  • 8) Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J., Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res., 59, 2615–2622 (1999).
  • 9) Momose, I., Sekizawa, R., Hashizume, H., Kinoshita, N., Homma, Y., Hamada, M., Iinuma, H., and Takeuchi, T., Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, isolation, physico-chemical properties and biological activities. J. Antibiotics, 54, 997–1003 (2001).
  • 10) Momose, I., Sekizawa, R., Hirosawa, S., Ikeda, D., Naganawa, H., Iinuma, H., and Takeuchi, T., Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. II. Structure determination and synthesis. J. Antibiotics, 54, 1004–1012 (2001).
  • 11) Momose, I., Sekizawa, R., Iinuma, H., and Takeuchi, T., Inhibition of proteasome activity by tyropeptin A in PC12 cells. Biosci. Biotechnol. Biochem., 66, 2256–2258 (2002).
  • 12) Momose, I., Umezawa, Y., Hirosawa, S., Iinuma, H., and Ikeda, D., Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg. Med. Chem. Lett., 15, 1867–1871 (2005).
  • 13) Tsubuki, S., Kawasaki, H., Saito, Y., Miyashita, N., Inomata, M., and Kawashima, S., Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome. Biochem. Biophys. Res. Commun., 196, 1195–1201 (1993).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.